Marshall Wace LLP Buys Shares of 161,846 Paysign, Inc. (NASDAQ:PAYS)

Marshall Wace LLP bought a new position in shares of Paysign, Inc. (NASDAQ:PAYS - Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor bought 161,846 shares of the company's stock, valued at approximately $489,000. Marshall Wace LLP owned approximately 0.30% of Paysign as of its most recent filing with the Securities & Exchange Commission.

Other large investors have also recently bought and sold shares of the company. Renaissance Technologies LLC raised its stake in shares of Paysign by 11.0% during the 4th quarter. Renaissance Technologies LLC now owns 1,501,622 shares of the company's stock worth $4,535,000 after purchasing an additional 149,200 shares in the last quarter. JPMorgan Chase & Co. raised its position in Paysign by 145.6% during the fourth quarter. JPMorgan Chase & Co. now owns 155,347 shares of the company's stock worth $469,000 after acquiring an additional 92,100 shares in the last quarter. Bank of New York Mellon Corp lifted its stake in Paysign by 31.3% in the fourth quarter. Bank of New York Mellon Corp now owns 94,515 shares of the company's stock valued at $285,000 after acquiring an additional 22,548 shares during the last quarter. WINTON GROUP Ltd grew its position in shares of Paysign by 514.9% in the 4th quarter. WINTON GROUP Ltd now owns 90,710 shares of the company's stock valued at $274,000 after acquiring an additional 75,959 shares during the period. Finally, Integrated Quantitative Investments LLC bought a new position in shares of Paysign in the 4th quarter valued at about $259,000. 25.89% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several brokerages recently issued reports on PAYS. DA Davidson reiterated a "buy" rating and issued a $6.00 target price on shares of Paysign in a research note on Wednesday, March 26th. Barrington Research reiterated an "outperform" rating and issued a $7.00 price objective on shares of Paysign in a report on Wednesday, March 26th.

Paysign Stock Performance

Shares of NASDAQ PAYS traded up $0.06 during trading hours on Thursday, reaching $2.39. 21,302 shares of the stock were exchanged, compared to its average volume of 203,616. The stock's fifty day simple moving average is $2.26 and its 200 day simple moving average is $2.85. The firm has a market capitalization of $128.46 million, a price-to-earnings ratio of 15.93 and a beta of 0.23. Paysign, Inc. has a 52 week low of $1.80 and a 52 week high of $5.59.

Paysign (NASDAQ:PAYS - Get Free Report) last posted its earnings results on Tuesday, March 25th. The company reported $0.02 earnings per share for the quarter, hitting analysts' consensus estimates of $0.02. Paysign had a return on equity of 30.64% and a net margin of 14.28%. The company had revenue of $15.61 million during the quarter, compared to the consensus estimate of $15.42 million. Research analysts predict that Paysign, Inc. will post 0.21 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, CEO Mark Newcomer sold 100,000 shares of the business's stock in a transaction that occurred on Monday, February 24th. The stock was sold at an average price of $2.73, for a total value of $273,000.00. Following the completion of the sale, the chief executive officer now directly owns 8,936,886 shares in the company, valued at approximately $24,397,698.78. The trade was a 1.11 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. Company insiders own 22.40% of the company's stock.

Paysign Company Profile

Paysign, Inc provides prepaid card programs, comprehensive patient affordability offerings, digital banking services, and integrated payment processing services for businesses, consumers, and government institutions. Its product offerings include solutions for corporate rewards, prepaid gift cards, general purpose reloadable debit cards, employee incentives, consumer rebates, donor compensation, clinical trials, healthcare reimbursement payments and pharmaceutical payment assistance, and demand deposit accounts accessible with a debit card.